Although this system is modulated in different experimental models of PD and in response to chronic levodopa treatment,51,79 it is not known whether these changes are compensatory or causal.80 Preclinical studies showed that both CB1R agonists and antagonists represent potentially useful antidyskinetic agents.69,74,81. This evidence concerns the gene CNR1 and Parkinson disease.